GSK Plc: Jemperli Trial Shows Unprecedented Results

(RTTNews) - GSK plc (GSK, GSK.L) reported longer-term results from the phase II supported collaborative study with Memorial Sloan Kettering Cancer Center evaluating Jemperli or dostarlimab as a first-line treatment-as an alternative to surgery-for mismatch repair deficient locally advanced rectal cancer. The trial showed 100% clinical complete response rate in 42 patients who completed treatment with dostarlimab.

Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: "We look forward to evaluating dostarlimab in certain colorectal cancers in our ongoing AZUR-1 and AZUR-2 registrational studies."

For More Such Health News, visit rttnews.com.